 DUBLIN, Ireland, Oct. 01, 2021 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option to purchase an aggregate of 100,000 ordinary shares of Nabriva Therapeutics as an inducement to Christopher Naftzger, Nabrivas newly appointed General Counsel. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. 